Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Disclosure of Invention In view of the above-mentioned disadvantages of the methods for synthesizing semaglutide in the prior art, the present invention provides a method for synthesizing semaglutide from Fmoc solid-phase polypeptide: a Linker of ionic liquid is additionally connected to a PS type solid phase carrier, and the hydrophobic property of the PS carrier is solved by utilizing the solubility property of the ionic liquid, so that the problem of poor coupling effect caused by the formation of a beta-folding secondary structure of partial residue of the semaglutide is solved
Those with personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, unstable cardiovascular disease, or severe renal impairment should not pursue this transition without specialized medical evaluation and documented contraindication review
6 (2017): 663678, 10.1111/jcpp.12684
Assuming a standard deviation for both endpoints of 0.18 and that 16 participants completed the study, then the 90% confidence interval (CI) for the estimated geometric mean ratio between IcoSema and one of the two components administered alone would range from 0.91 to 1.10 times the geometric mean ratio with 90% probability
US$ 24.25
US$ 28.60
US$ 28.48
US$ 28.79
